Keros Therapeutics Inc
NASDAQ:KROS

Watchlist Manager
Keros Therapeutics Inc Logo
Keros Therapeutics Inc
NASDAQ:KROS
Watchlist
Price: 14.57 USD 2.9% Market Closed
Market Cap: 591.7m USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
+103%
Revenue
Forecast
+69%
Operating Income
Forecast
-1%
Net Income
Forecast
+1%

Wall Street
Price Targets

KROS Price Targets Summary
Keros Therapeutics Inc

Wall Street analysts forecast KROS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KROS is 29.58 USD with a low forecast of 15.15 USD and a high forecast of 43.05 USD.

KROS Lowest Forecast
Wall Street Target
15.15 USD
4% Upside
KROS Average Forecast
Wall Street Target
29.58 USD
103% Upside
KROS Highest Forecast
Wall Street Target
43.05 USD
195% Upside
Lowest
Price Target
15.15 USD
4% Upside
Average
Price Target
29.58 USD
103% Upside
Highest
Price Target
43.05 USD
195% Upside
Keros Therapeutics Inc Competitors:
Price Targets
BCRX
BioCryst Pharmaceuticals Inc
65% Upside
GILD
Gilead Sciences Inc
9% Upside
ALKS
Alkermes Plc
38% Upside
INMB
INmune Bio Inc
227% Upside
BCRX
BioCryst Pharmaceuticals Inc
65% Upside
GILD
Gilead Sciences Inc
9% Upside
ALKS
Alkermes Plc
38% Upside
INMB
INmune Bio Inc
227% Upside
MDGL
Madrigal Pharmaceuticals Inc
61% Upside
S
6955
Shandong Boan Biotechnology Co Ltd
1% Upside
ACAD
ACADIA Pharmaceuticals Inc
12% Upside
IGMS
IGM Biosciences Inc
53% Upside

Revenue
Forecast

Revenue Estimate
Keros Therapeutics Inc

For the last 5 years the compound annual growth rate for Keros Therapeutics Inc's revenue is -19%. The projected CAGR for the next 3 years is 69%.

-19%
Past Growth
69%
Estimated Growth
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Keros Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Keros Therapeutics Inc

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-39%
Average Miss
What are analyst estimates?

See Also

Summary
KROS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KROS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KROS stock valuation using valuation multiples.
Wall Street Estimates
KROS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KROS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KROS's stock price target?
Price Target
29.58 USD

According to Wall Street analysts, the average 1-year price target for KROS is 29.58 USD with a low forecast of 15.15 USD and a high forecast of 43.05 USD.

What is Keros Therapeutics Inc's Revenue forecast?
Projected CAGR
69%

For the last 5 years the compound annual growth rate for Keros Therapeutics Inc's revenue is -19%. The projected CAGR for the next 3 years is 69%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.